The following is a summary of “Radiofrequency Ablation Versus Stereotactic Body Radiotherapy for Recurrent Small ...

In January 2024, the FDA approved erdafitinib (Balversa) for adult patients with locally advanced or metastatic urothelial ...

Monjuvi plus Revlimid and Rituxan demonstrated improved progression-free survival for patients with relapsed or refractory ...

Advances in therapy are improving outcomes for patients, but the incidence and mortality rates for hepatocellular carcinoma ...

GSK said on Friday the addition of its cancer drug Jemperli to both standard of care chemotherapy and Zejula maintenance ...

CURE® highlights some of the top stories from SABCS, including those focused on older and younger patients with breast cancer ...

Addition of the CDK 4/6 inhibitor improved progression-free survival by 15.2 months for patients with HR+/HER2+ advanced ...

AbbVie (NYSE: ABBV) recently announced new results from two ongoing clinical trials evaluating epcoritamab, a CD3xCD20 bispecific T-cell-engaging antibody administered subcutaneously, in adult ...

Results of a retrospective study of a racially diverse population demonstrated positive outcomes for patients with NSCLC who experience irAEs when treated with immune checkpoint inhibitors.

British drug maker AstraZeneca Plc (AZN.L, AZN) announced Monday that the European Commission has approved Tagrisso (osimertinib) to ...